Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: A European perspective

American Journal on Addictions

Volumn 12, Issue SUPPL. 1, 2003, Pages s69-s80

  Soyka, Michael ^a   Chick, Jonathan ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; N METHYL DEXTRO ASPARTIC ACID; NALMEFENE; NALTREXONE; PLACEBO;

ABSTINENCE; ALCOHOLISM; ARTICLE; CALCULATION; CLINICAL TRIAL; DETOXIFICATION; DRINKING BEHAVIOR; DRUG EFFICACY; DRUG MECHANISM; HUMAN; META ANALYSIS;

EID: 0038587645     PISSN: 10550496     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2003.tb00497.x     Document Type: Article

References (72)

1. Bisaga A, Popik P. In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-D-aspartate (NMDA) antagonists. Drug Alcohol Depend. 2000;59:1-15.
2. Lovinger DM, White G, Weight FF. Ethanol inhibits NMDA-activated ion current in hippocampal neurons. Science. 1989;243:1721.
3. Lovinger DM, White G, Weight FF. NMDA receptor-mediated synaptic excitation selectively inhibited by ethanol in hippocampal slice from adult rat. J Neurosci. 1990;10:280-284.
4. Lovinger DM. Excitotoxicity and alcoholrelated brain damage. Alcohol Clin Exp. Res. 1993;17:19-27.
5. Shen EH, Phillips TJ. MK-801 potentiates ethanol's effects on locomotor activity in mice. Pharmacol Biochem Behav. 1998;59:135-143.
6. Broadbent J, Weitemier AZ. Dizocilpine (MK-801) prevents the development of sensitization to ethanol in DBA/2J mice. Alcohol Alcohol. 1999;34:283-288.
7. Johnson BA, Ait-Daoud N. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology. 2000;149:327-344.
8. Tsai G, Gastfriend DR, Coyle JT. The glutamatergic basis of human alcoholism. Am J Psychiatry. 1995;152:332-340.
9. Danysz W, Jankowska E, Glazewski S, Kostowski W. The involvement of NMDA receptors in acute and chronic effects of ethanol. Alcohol Clin Exp Res. 1992;16:499-504.
10. Krystal JH, Petrakis IL, Webb E, et al. Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch Gen Psychiatry. 1998;55:354-360.
11. Trevisan L, Fitzgerald LW, Brose N, et al. Chronic ingestion of ethanol up-regulates NMDA R1 subunit immunoreactivity in rat hippocampus. J Neurochem. 1994;62:1635-1638.
12. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001;245:1734-1739.
13. Schuetz C, Soyka M. Dextrometorphan challenge in alcoholics and healthy controls. Arch Gen Psychiatry. 2000;57:291-292.
14. Littleton J. Acamprosate - how does it work? Addiction. 1995;90:1179-1188.
15. Rammes G, Mahal B, Putzke J, Parsons C, et al. The anti-craving compound acamprosate acts as weak NMDA-receptor antagonist but modulates NMDA-receptor subunit expression similar to memantine and MK-801. Neuropharmacology. 2001;40:749-760.
16. Zieglgaensberger W, Hauser C, Wetzel C, et al. Actions of acamprosate on neurons of the central nervous system. In: Soyka M, ed. A camprosate in Relapse Prevention of Alcoholism. Berlin, Heidelberg, New York: Springer; 1996:65-70.
17. Zieglgaensberger W, Zeise M. Calcium-diacetyl-homotaurinate which prevents relapse in weaned alcoholics decreases the action of excitatory amino acids in neocortical neurons of the rat in vitro. In: Sellers EM, Naranjo CA, eds. Novel Pharmacological Interventions for Alcoholism. Heidelberg, New York: Springer; 1992:337-341.
18. Berton F, Francesconi WG, Madamba SG, Zieglgänsberger W, Siggins GR. Acamprosate enhances N-methyl-D-apartate receptor-mediated neurotransmission but inhibits presynaptic GABA (B) receptors in nucleus accumbens neurons. Alcohol Clin Exp Res. 1998;22:183-191.
19. Dahchour A, De Witte P, Bolo N, et al. Central effects of acamprosate, part 1: acamprosate blocks the glutatamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats. Psychiatry Res Neuroimaging. 1998;82:107-114.
20. Bolo N, Nedelec JF, Muzet M, de Witte P, Dahchour A, Durbin P, Macher JP. Central effects of acamprosate, part 2: acamprosate modifies brain in-vivo proton magnetic resonance spectrum in healthy young male volunteers. Psychiatr Res. 1998;82:115-127.
21. al Qatari M, Bouchenafa O, Littleton J. Mechanisms of action of acamprosate, part II: ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res. 1998;22:810-814.
22. Mayer S, Harris B, Gibson DA, Blanchard J, et al. Acamprosate has no effect on NMDA-induced toxicity but reduces toxicity induced by spermidine or by changing the medium in organotypic hippocampal slice cultures from rat. Alcohol Clin Exp Res. 2002;26:655-662.
23. Putzke J, Spanagel R, Tolle TR, Zieglgänsberger W. The anti-craving drug acamprosate reduces c-fos expression in rats undergoing ethanol withdrawal. Eur J Pharmacol. 1996;317:39-48.
24. Schuele C, Laakmann G, Baghai T, Neukam C, Soyka M. Lack of effects of acamprosate on anterior pituitary hormone secretion in healthy subjects. J Clin Psychopharmacol. 1999;4:387-389.
25. al Qatari M, Khan S, Harris B, Littleton J. Acamprosate is neuroprotectivc against glutamate-induced excitotoxicity when enhanced by ethanol withdrawal in neocortical cultures of fetal rat brain. Alcohol Clin Exp Res. 2001;25:1276-1283.
26. Koob GF, Mason BJ, De Witte P, Littleton J, Siggins GR. Potential neuroprotective effects on acamprosate. Alcohol Clin Exp Res. 2002;26:280-286.
27. Myrick H, Brady KT, Malcolm R. New developments in the pharmacotherapy of alcohol dependence. Am J Addict. 2001;10:3-15.
28. Schneider U, Wohlfarth K, Schulze-Binhage A, Haaker T, Muller-Vahl KR, Zedler M, Becker H, Dengler R, Emrich HM. Effects of acamprosate on memory in healthy young subjects. J Stud Alcohol. 1999;60:172-175.
29. Soyka M, Aichmüller C, Preuss U, Möller HJ. Effects of acamprosate on psychomotor performance and driving ability in abstinent alcoholics. Pharmacopsychiatry. 1998;31:232-235.
30. Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA. 1999;281:1318-1325.
31. Mason BJ, Ownby RL. Acamprosate for the treatment of alcohol dependence: a review of double-blind pacebo-controlled trials. CNS Spectrums. 2000;5:58-69.
32. Soyka M. Relapse prevention in alcoholism: recent advances and future possibilities. CNS Drugs. 1997;7:313-327.
33. Wilde MI, Wagstaff AJ. Acamprosate: a review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs. 1997;53:1038-1053.
34. Chick J, Lehert Ph, Landron F. Does acamprosate improve control of drinking as well as aiding abstinence? Alcohol Clin Exp Res. 2002;26(Suppl):475A.
35. Slattery J, Chick J, Cochrane M, Craig J, Godfrey C, Kohli H, MacPherson K, Parrot S, Quinn S, Tochel C, Watson H. Prevention of relapse in alcohol dependence. Health Technology Assessment Report 3, Glasgow, Health Technology Board of Scotland. 2003. Available at: http://www.htbs.co.uk.
36. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res. 2001;25:1335-1341.
37. SBU. Behandling av Alkohol-och Narkotikaproblem. En Evidensbaserad Kunskapssammanställning. Stockholm: 2001. Statens beredning för medicinsk utvärdering, rapport nr 156. http://www.sbu.com. Accessed March 16, 2003.
38. Lehert Ph. Review and discussion of statistical analysis of controlled clinical trials in alcoholism. Alcohol Alcohol (Suppl) 1993;2:157-163.
39. Lhuintre JP, Moore N, Tran G, et al. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol. 1990;25:613-622.
40. Kranzler HR, Escobar R, Lee D-K, Meza E. Elevated rates of early discontinuation from pharmacotherapy trials in alcoholics and drug abusers. Alcohol Clin Exp Res. 1996;20:16-20.
41. Paille FM, Guelfi JD, Perkins AC, et al. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1995;30:239-247.
42. Chick J, Howlett H, Morgan MY, Ritson B. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol. 2000;35:176-187.
43. Roussaux JP, Hers D, Ferauge M. Does acamprosate diminish the appetite for alcohol in weaned alcoholics? J Pharm Belg. 1996;51:65-68.
44. Ansoms C, Deckers F, Lehert P, Pelc I, Potgieter A. An open study with acamprosate in Belgium and Luxemburg: results on sociodemographics, supportive treatment, and outcome. Eur Addict Res. 2000;6:132-140.
45. Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol-Clin Exp Res. 1998;22:573-579.
46. Geerlings PJ, Ansoms C, van den Brink W. Acamprosate and prevention of relapse in alcoholics. Eur Addict Res. 1997;3:129-137.
47. Gual A, Lehert Ph. Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol. 2001;36:413-418.
48. Pelc I, Le Bon O, Verbanck P, Lehnert PH, Opsomer L. Calcium acetyl homotaurinate for maintaining abstinence in weaned alcoholic patients: a placebo-controlled double-blind multicentre-study. In: Naranjo C, Sellers EM, eds. Novel Pharmacological Interventions for Alcoholism. New York: Springer; 1992:348-352.
49. Pelc I, Verbanek P, Le Bon O, Gavrilovic M, Lion K, Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients: a 90-day placebo-controlled dose-finding study. Br J Psychiatry. 1997;171:73-77.
50. Poldrugo F. Acamprosate treatment in a longterm community-based alcohol rehabilitation programme. Addiction. 1997;92:1537-1546.
51. Sass H, Soyka M, Mann K, Zieglgänsberger W. Relapse prevention by acamprosate: results from a placebo-controlled study in alcohol dependence. Arch Gen Psychiatry. 1996;53:673-680.
52. Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol. 2000;35:202-209.
53. Whitworth AB, Fischer F, Lesch OM, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet. 1996;347:1438-1442.
54. Hopkins JS, Garbutt JC, Poole CL, West SL, Carey TS. Naltrexone and acamprosate: meta-analysis of two medical treatments for alcoholism. Alcohol Clin Exp Res. 2002;26(Suppl):130A.
55. Namkoong K, Lee B-O, Lee P-G, Choi M-J, Lee E. 2003. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol. 2003;38:135-141.
56. Scottish Intercollegiate Guidelines Network (SIGN). Secondary Prevention of Coronary Heart Disease Following Myocardial Infarction. Edinburgh: SIGN;2000. SIGN publication no. 41. Available at: http://www.sign.ac.uk. Accessed March 16, 2003.
57. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 1997;277(9):739-745.
58. Soyka M, Preuss U, Schütz C. Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism: results from a non-blind, multicentre study. Drugs R D. 2002;3:1-12.
59. De Wildt WA, SchippersGM, van den Brink W, Potgieter AS, Decker F, Bets D. Does psychosocial treatment enhance the efficacy of acamprosate in patients with alcohol problems? Alcohol Alcohol. 2002;37:375-382.
60. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek J. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology. 2002;160:19-29.
61. Srisurapanont M, Jarusuraisin N. Opioid antahonists for alcohol dependence. Cochrane Database Syst Rev. 2002: CD001867.
62. Rubio G, Jimenez-Arriero MA, Ponce G, Palomo T. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcohol. 2001;36:419-425.
63. Streeton C, Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol. 2001;36:544-552.
64. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992;49:881-887.
65. Heinälä P, Kuoppasalmi K, Lönnqvist J, Kiianmaa K, Sinclair D, Alho H. Targeted use of naltrexone in the treatment of alcohol dependence - a double-blind placebo-controlled Finnish trial. J Psychopharmacol. 2001;21:287-292.
66. Chick J, Anton R, Checinski K, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000;35:587-593.
67. Gastpar M, Bonnet U, Böning J, et al. Lack of efficacy of naltrexone in the prevention of alcohol relapse - results from a German multicenter study. J Clin Psychopharmacol. 2002;8:195-200.
68. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992,49:876-880.
69. Balldin J, Berglund M, Borg S. The Swedish naltrexone study: present results. Eur Psychiatry 1998;14 (supp 14):154s (abstract).
70. Guardia J, Caso C, Arias F, Gual A, Sanahuja J, Ramirez M, Mengual I, Gonzalvo B, Segura L, Trujols J, Casas M. A double-blind placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicentre clinical trial. Alcohol Clin Exp Res. 2002;26(9):1381-1387.
71. Miotto K, McCann M, Basch J, Rawson R, Ling W. Naltrexone and dysphoria: fact or myth? Am J Addict. 2002;11:151-160.
72. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Kämpf P, Stracke R, Baehr M, Naber D, Wiedemann K. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003;60(1):92-99.